This study is looking at how two medications, atomoxetine (Strattera) and DAW2022, might help people with obstructive sleep apnea (OSA). OSA is a common condition where breathing repeatedly stops and starts during sleep. Researchers want to see if combining atomoxetine and DAW2022 can reduce how severe your OSA is. You could be eligible if you are between 21 and 70 years old and have moderate-to-severe OSA (meaning you have at least 15 breathing pauses or shallow breaths per hour during sleep). The study will measure the effect of these drugs on your OSA severity after one week of treatment. The current recruitment status is unclear, and they plan to enroll 18 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It involves a drug night and a placebo night, with a month-long break between treatments.

What's involved

You would have two overnight sleep studies, where your sleep and breathing are monitored. Before each study night, you'll have a physical exam and, if you're a premenopausal woman, a pregnancy test. You will take atomoxetine for seven days (40 mg for 3 days, then 80 mg for 4 days) and DAW2022 for seven days (34 mg).

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured at one week, after the drug and placebo treatments.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.